Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

Patients with gastroesophageal reflux disease (GERD) are either treated for 4 weeks with a standard dose (20mg) of omeprazole, a drug of first choice, or by an individualized dosing (20 or 60mg/day) according how fast the patient can metabolize (eliminate) the drug. The individual elimination capacity is genetically controlled and therefore all patients will be genotyped prior to therapy.

Inclusion Criteria:

• Patients with GERD grade A and B (mild to moderate severe disease) diagnosed by routine endoscopy will be recruited in different clinical and ambulant centres of gastroenterology; written informed consent is obligatory
• Range of Age: 20-70
• BMI: 20-30

Exclusion Criteria:

• Patients who are allergic to proton-pump inhibitors or show incompatibility
• Patients who have lactase deficiency
• Patients who have severe chronic disease
• Patients who participated in another study during the last three months
• Patients who are pregnant